|
1
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: state
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ando K, Heymann MF, Stresing V, Mori K,
Redini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers. 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abelson PH: Medicine from plants. Science.
247:5131990. View Article : Google Scholar
|
|
4
|
Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S
and Ikejima T: Fas/FasL signaling allows extracelluar-signal
regulated kinase to regulate cytochrome c release in
oridonin-induced apoptotic U937 cells. Biol Pharm Bull.
29:1873–1879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Y, Xie L, Chen G, Wang H and Zhang R:
Effects of oridonin on proliferation of HT29 human colon carcinoma
cell lines both in vitro and in vivo in mice. Pharmazie.
62:439–444. 2007.PubMed/NCBI
|
|
6
|
Hsieh TC, Wijeratne EK, Liang JY,
Gunatilaka AL and Wu JM: Differential control of growth, cell cycle
progression, and expression of NF-kappaB in human breast cancer
cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin,
diterpenoids from the chinese herb Rabdosia rubescens.
Biochem Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou GB, Kang H, Wang L, et al: Oridonin,
a diterpenoid extracted from medicinal herbs, targets AML1-ETO
fusion protein and shows potent antitumor activity with low adverse
effects on t (8;21) leukemia in vitro and in vivo. Blood.
109:3441–3450. 2007. View Article : Google Scholar
|
|
8
|
Jin S, Shen JN, Wang J, Huang G and Zhou
JG: Oridonin induced apoptosis through Akt and MAPKs signaling
pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Behrens J and Lustig B: The Wnt connection
to tumorigenesis. Int J Dev Biol. 48:477–487. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barker N and Clevers H: Mining the Wnt
pathway for cancer therapeutics. Nat Rev Drug Discov. 5:997–1014.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin YC, You L, Xu Z, et al: Wnt signaling
activation and WIF-1 silencing in nasopharyngeal cancer cell lines.
Biochem Biophys Res Commun. 341:635–640. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weeraratna AT, Jiang Y, Hostetter G, et
al: Wnt5a signaling directly affects cell motility and invasion of
metastatic melanoma. Cancer Cell. 1:279–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wissmann C, Wild PJ, Kaiser S, et al:
WIF1, a component of the Wnt pathway, is down-regulated in
prostate, breast, lung, and bladder cancer. J Pathol. 201:204–212.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoang BH, Kubo T, Healey JH, et al:
Expression of LDL receptor-related protein 5 (LRP5) as a novel
marker for disease progression in high-grade osteosarcoma. Int J
Cancer. 109:106–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iozzo RV, Eichstetter I and Danielson KG:
Aberrant expression of the growth factor Wnt-5A in human
malignancy. Cancer Res. 55:3495–3499. 1995.PubMed/NCBI
|
|
16
|
Lu BJ, Wang YQ, Wei XJ, et al: Expression
of WNT-5a and ROR2 correlates with disease severity in
osteosarcoma. Mol Med Rep. 5:1033–1036. 2012.PubMed/NCBI
|
|
17
|
Ma Y, Ren Y, Han EQ, et al: Inhibition of
the Wnt-beta-catenin and Notch signaling pathways sensitizes
osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun.
431:274–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kansara M, Tsang M, Kodjabachian L, et al:
Wnt inhibitory factor 1 is epigenetically silenced in human
osteosarcoma, and targeted disruption accelerates
osteosarcomagenesis in mice. J Clin Invest. 119:837–851. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao FH, Hu XH, Li W, et al: Oridonin
induces apoptosis and senescence in colorectal cancer cells by
increasing histone hyperacetylation and regulation of p16, p21, p27
and c-myc. BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He BC, Chen L, Zuo GW, et al: Synergistic
antitumor effect of the activated PPARgamma and retinoid receptors
on human osteosarcoma. Clin Cancer Res. 16:2235–2245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu K, Yang Q, Mu Y, et al: Berberine
inhibits the proliferation of colon cancer cells by inactivating
Wnt/beta-catenin signaling. Int J Oncol. 41:292–298.
2012.PubMed/NCBI
|
|
22
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang N, Song WX, Luo J, et al:
BMP-9-induced osteogenic differentiation of mesenchymal progenitors
requires functional canonical Wnt/beta-catenin signalling. J Cell
Mol Med. 13:2448–2464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He BC, Gao JL, Luo X, et al: Ginsenoside
Rg3 inhibits colorectal tumor growth through the down-regulation of
Wnt/β-catenin signaling. Int J Oncol. 38:437–445. 2011.PubMed/NCBI
|
|
25
|
Park HR and Park YK: Expression of p53
protein, PCNA, and Ki-67 in osteosarcomas of bone. J Korean Med
Sci. 10:360–367. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davidson G and Niehrs C: Emerging links
between CDK cell cycle regulators and Wnt signaling. Trends Cell
Biol. 20:453–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lustig B and Behrens J: The Wnt signaling
pathway and its role in tumor development. J Cancer Res Clin Oncol.
129:199–221. 2003.PubMed/NCBI
|
|
28
|
Nakamura T, Hamada F, Ishidate T, et al:
Axin, an inhibitor of the Wnt signalling pathway, interacts with
beta-catenin, GSK-3beta and APC and reduces the beta-catenin level.
Genes Cells. 3:395–403. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar
|
|
30
|
Bikkavilli RK, Feigin ME and Malbon CC:
p38 mitogen-activated protein kinase regulates canonical
Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci.
121:3598–3607. 2008. View Article : Google Scholar
|
|
31
|
Li CY, Wang EQ, Cheng Y and Bao JK:
Oridonin: an active diterpenoid targeting cell cycle arrest,
apoptotic and autophagic pathways for cancer therapeutics. Int J
Biochem Cell Biol. 43:701–704. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang CL, Wu LJ, Zuo HJ, Tashiro S,
Onodera S and Ikejima T: Cytochrome c release from oridonin-treated
apoptotic A375-S2 cells is dependent on p53 and extracellular
signal-regulated kinase activation. J Pharmacol Sci. 96:155–163.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera
S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via
activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK
survival pathway in murine fibrosarcoma L929 cells. Arch Biochem
Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu HZ, Yang YB, Xu XD, et al: Oridonin
induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa
cell line. Acta Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, Li X, Wang J, Ye Z and Li JC:
Oridonin up-regulates expression of P21 and induces autophagy and
apoptosis in human prostate cancer cells. Int J Biol Sci.
8:901–912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.
|
|
37
|
Baron R and Kneissel M: WNT signaling in
bone homeostasis and disease: from human mutations to treatments.
Nat Med. 19:179–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haydon RC, Deyrup A, Ishikawa A, et al:
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein
is a frequent event in human osteosarcoma. Int J Cancer.
102:338–342. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rubin EM, Guo Y, Tu K, Xie J, Zi X and
Hoang BH: Wnt inhibitory factor 1 decreases tumorigenesis and
metastasis in osteosarcoma. Mol Cancer Ther. 9:731–741. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo Y, Rubin EM, Xie J, Zi X and Hoang BH:
Dominant negative LRP5 decreases tumorigenicity and metastasis of
osteosarcoma in an animal model. Clin Orthop Relat Res.
466:2039–2045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mishra R: Glycogen synthase kinase 3 beta:
can it be a target for oral cancer. Mol Cancer. 9:1442010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu J, Liao Q, He H, Zhong D and Yin K:
TWIST interacts with beta-catenin signaling on osteosarcoma cell
survival against cisplatin. Mol Carcinog. Dec 31–2012.(Epub ahead
of print). View Article : Google Scholar
|
|
44
|
Xia JJ, Pei LB, Zhuang JP, et al:
Celecoxib inhibits beta-catenin-dependent survival of the human
osteosarcoma MG-63 cell line. J Int Med Res. 38:1294–1304. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cai Y, Mohseny AB, Karperien M, Hogendoorn
PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway
in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang QL, Xie XB, Wang J, et al: Glycogen
synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of
human osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zorn AM: Wnt signalling: antagonistic
Dickkopfs. Curr Biol. 11:R592–R595. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kawano Y and Kypta R: Secreted antagonists
of the Wnt signalling pathway. J Cell Sci. 116:2627–2634. 2003.
View Article : Google Scholar
|
|
49
|
Lin CH, Guo Y, Ghaffar S, et al: Dkk-3, a
secreted wnt antagonist, suppresses tumorigenic potential and
pulmonary metastasis in osteosarcoma. Sarcoma.
2013:1475412013.PubMed/NCBI
|
|
50
|
Hoang BH, Kubo T, Healey JH, et al:
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma
cells by modulating the Wnt-beta-catenin pathway. Cancer Res.
64:2734–2739. 2004. View Article : Google Scholar : PubMed/NCBI
|
